Natera NTRA

Reference table

1. Data integrity — what we rejected before writing a line

Vendor corruption is a routine feature of this feed and this file has one significant instance plus several gaps. Stated plainly:

REJECTED — the entire forecast EBITDA and EBIT series in est. Every forecast year carries a large negative EBITDA alongside a positive, rising net income: FY26E EBITDA −$1,050.0M, FY27E −$1,249.4M, FY28E −$1,507.2M, FY29E −$1,774.4M, FY30E −$2,097.9M, while net income runs −$232.3M (FY26E), −$26.3M (FY27E), +$225.9M (FY28E), +$331.8M (FY29E), +$720.2M (FY30E). By FY30 the file asserts EBITDA is $2.82B below net income, which is arithmetically impossible — EBITDA sits above net income by definition of depreciation, interest and tax. The associated sgaExpenseAvg line ($1,740.9M FY26E rising to $3,478.3M FY30E) appears to have absorbed cost of goods sold, which is the likely mechanical cause. We use only the revenueAvg and epsAvg lines from est; every cost and margin forecast in that block is discarded.

ACCEPTED with a note — the epsAvg line. It survives an internal check: FY26E of −$1.617 is consistent with the Q1'26 actual of −$0.60 and the Q2 consensus of −$0.494, and the analyst counts are respectable (11-14 on EPS, 15-16 on revenue). We use it.

GAP — product-line revenue is unusable. seg_prod splits FY25 into "Product" $2,295.8M and "Licensing and other" $10.3M. There is no oncology / women's health / organ health breakdown anywhere in this file for FY24 or FY25. FY23 carried slightly more detail ("Oncology products" $19.3M, "Genetic testing services" $18.3M) but those figures are too small to be the real segment lines. We therefore cannot verify from this data how the growth splits across franchises, and no claim in this dive rests on such a split.

GAP — no meaningful analyst-count depth beyond FY28. FY29E and FY30E rest on 8 and 12 EPS contributors respectively; the FY28E EPS range alone spans −$1.20 to +$4.57, a $5.77 spread on a $1.52 midpoint. The FY28 profitability crossover is therefore a consensus hope with enormous dispersion, not a forecast. We do not build the base case on it.

CLEAN — quarterly income statement, balance sheet, cash flow. The FY25 quarterly revenue sum ($501.8M + $546.6M + $592.2M + $665.5M = $2,306.1M) reconciles exactly to the annual line. Quarterly net income sums to −$208.2M, matching the annual figure. Share counts progress sensibly (122.9M to 141.5M). No sign flips, no zeroed fields, no duplicated rows. inc_q[0] — the usual offender — is internally consistent here: revenue $696.6M, gross profit $451.4M (64.8%), operating loss −$93.5M, net loss −$85.1M, EPS −$0.60 on 141.5M shares (−85.091/141.502 = −$0.601). Confirmed.

NOTE — market cap versus share count. The quote's $38.72B at $270.36 implies ~143.2M shares against the 141.5M weighted diluted count in Q1'26 — a ~1.2% discrepancy, consistent with share issuance since the quarter end. Immaterial; we use 141.5M for per-share arithmetic and flag it.

2. What they actually sell, and what the numbers say about it

Natera describes three product families in its profile: reproductive health (Panorama non-invasive prenatal testing, Vistara single-gene screening, Horizon carrier screening, Spectrum for IVF, Anora miscarriage analysis, non-invasive paternity), oncology (Signatera circulating-tumour-DNA residual-disease monitoring), and organ-health/transplant surveillance. 6,140 employees.

The vendor gives us no segment split, so the case has to be built from the consolidated numbers — and those are unusually informative:

Read the gross margin row first. It is the whole story. Between FY23 and FY25 revenue grew 113% while gross margin expanded 19.3 percentage points. That combination — volume doubling and unit economics improving — is what separates a scaling diagnostics franchise from a price-taking laboratory. It reflects fixed-cost absorption across a sequencing platform plus, almost certainly, improving reimbursement realisation on the oncology line. It is the single most defensible fact in this file.

Read the operating-income row second, and be honest about it. FY25's operating loss (−$309.9M) was wider than FY24's (−$222.3M) despite $609.2M more revenue. Q1'26's loss (−$93.5M) was wider than Q1'25's (−$79.2M) despite $194.8M more revenue. Natera is deliberately spending the gross-margin windfall: R&D went from $404.1M to $624.1M (+54.4%), SG&A from $841.3M to $1,177.3M (+39.9%). That is a defensible choice — it is what a company does when it believes it is in a land-grab — but it means the "operating leverage arrives automatically" argument is not yet supported by the reported numbers. Anyone underwriting the FY28 profitability crossover is underwriting a decision management has not yet made.

Read the cash-flow row third, because it reconciles the two. FY25 operating cash flow was +$215.3M against a −$208.2M net loss — a $423.5M gap, of which $354.4M is stock-based compensation. So the GAAP loss is roughly 1.7x covered by non-cash compensation alone. Free cash flow was +$109.1M after $106.2M of capex. Natera is not burning cash. It is reporting a loss while generating cash, which is a materially different and better situation than the headline suggests — but note the corollary: 14.9% of revenue is being paid in stock, which is real dilution (shares outstanding rose from 122.9M in Q2'24 to 141.5M in Q1'26, +15.1% in seven quarters).

Geography is a concentration, not a footnote. FY25: United States $2,264.3M, EMEA/India/Africa $24.5M, Americas ex-US $9.4M, Asia-Pacific $8.0M. That is 98.2% United States, and it has been ~98% every year since FY21 (FY21: $590.9M of $625.5M = 94.5%; FY23: $1,047.6M of $1,082.6M = 96.8%; FY24: 97.7%). International is not a growth lever in this business as currently run — it is a rounding error that has stayed a rounding error for five years. Any long-horizon model that leans on geographic expansion is unevidenced by this data.

3. The revenue-beat pattern — the strongest quantitative fact in the file

Five consecutive quarters, actual revenue versus the consensus estimate carried into the print:

Mean beat: +13.1%. Minimum beat: +10.2%. Not one miss. This is not noise — it is a systematic modelling shortfall, and the most likely explanation is that the sell-side models test volume off historical run-rates while the oncology surveillance cohort compounds (each retained patient generates repeat tests, so the base grows even before new patient adds).

Now apply it to the coming print. The consensus for 2026-08-06 is $661.2M — which is $35.4M BELOW the $696.6M Natera actually reported in Q1'26. The street is modelling a 5.1% sequential decline in a business that has grown sequentially in every one of the last eight quarters (413.4 → 439.8 → 476.1 → 501.8 → 546.6 → 592.2 → 665.5 → 696.6). Even a flat quarter is a 5% beat; a normal sequential advance is a 12-15% beat consistent with the pattern above.

This is the most exploitable observation in the dive — and it is also why the Hold is a Hold rather than an Avoid. The setup is asymmetric on the revenue line. What it is not asymmetric on is EPS: on the earnings line Natera has missed three of the last five (−$0.56 vs −$0.542; −$0.64 vs −$0.386; −$0.74 vs −$0.615) and beaten two (+$0.35 vs −$0.512; −$0.50 vs −$0.640). Revenue beats, EPS does not — because they spend the beat. A trader positioning for the revenue surprise must accept that the stock has, in the past, sold off on exactly that combination.

4. Profitability — where the crossover actually is, and how fragile it is

Consensus EPS: −$1.617 (FY26E, 11 analysts) → −$0.298 (FY27E, 12) → +$1.522 (FY28E, 14) → +$2.427 (FY29E, 8) → +$5.267 (FY30E, 12).

Two observations that matter more than the midpoints:

First, the FY28 crossover has enormous dispersion. The FY28E EPS range runs from −$1.200 to +$4.572 — a $5.77 spread around a $1.52 midpoint. That is not a forecast; that is fourteen analysts disagreeing about whether the company will be profitable at all in three years. Compare FY26E, where the range is −$1.800 to −$1.515 (a $0.28 spread) — the near term is well understood, the crossover is not.

Second, the profitability path is a decision, not a mechanic. Gross profit is already $1.50B annually. Operating expenses (R&D $624.1M + SG&A $1,177.3M = $1,801.4M) exceed it by $305.9M. To reach the FY28 midpoint, revenue has to grow to $4,014.9M (+74% from FY25) at, say, a 66% gross margin — $2,650M of gross profit — while operating expenses grow only ~40% to ~$2,520M. That requires management to let opex grow at roughly half the rate of revenue for three consecutive years, having done the exact opposite in FY25 and Q1'26. It is achievable. It is not automatic. Anyone paying 13.5x forward revenue is paying for it in advance.

Q4'25 is the proof-of-concept and should be read carefully. That quarter printed +$47.3M of net income and +$0.35 of EPS against a −$0.512 consensus — a genuine GAAP profit. Then Q1'26 immediately reverted to −$85.1M and −$0.60. One profitable quarter in a five-year run is evidence the model can work at scale; it is not evidence that it has.

5. Balance sheet and the funding question (there isn't one)

• Cash and equivalents: $1,076.1M (FY25), up from $945.6M (FY24) and $642.1M (FY23).
• Total debt: $214.4M, of which $0 is long-term — the entire balance is short-term ($80.3M) plus lease-type obligations. The company retired $282.9M of long-term debt between FY23 and FY24.
• Net cash: $861.8M, or ~$6.09 per share (2.3% of the market capitalisation).
• Current ratio: 2.96x. Quick ratio 2.83x. Cash ratio 1.95x — the company could settle every current liability from cash alone twice over.
• Working capital: $1,093.6M. Days sales outstanding 60.9, days inventory 29.6, cash conversion cycle 64.4 days.
• Equity: $1,712.4M, against accumulated deficit of −$2,776.0M — i.e. the company has raised and spent $4.5B to build this position. That is sunk, but it explains the price-to-book of 21.6x.
• Goodwill: $141.1M (first appeared in FY25; $0 in FY24 and FY23), from $16.0M of net acquisitions. Immaterial — this is an organically built business.

There is no financing risk in this story. No debt maturity wall, no covenant, no dilutive raise pending. The only dilution is compensatory: 14.9% of revenue paid in stock, driving the share count from 122.9M (Q2'24) to 141.5M (Q1'26). At $270 per share, $354.4M of annual stock compensation is ~1.3M shares a year of ongoing dilution — noticeable but not destabilising.

6. Valuation — what growth is priced at $270.36

At $270.36 (market cap $38.72B, net cash $861.8M, EV ~$37.86B):

Against the peer set the vendor supplies, Natera at 15.1x trailing EV/revenue is by a wide margin the most expensively valued diagnostics asset listed (DGX $25.6B cap, ILMN $30.0B, IQV $38.4B — all businesses of comparable or larger revenue at a fraction of the multiple). That premium is earned by the growth rate and the gross margin, but it is a premium that has to keep being earned every quarter.

6a. What today's price assumes (the inversion)

Reverse-engineering $270.36 into falsifiable claims. Each is consensus-derived arithmetic, labelled as such — not a Synthos forecast.

• Revenue compounds at ≥19% annually through FY28. At 11.4x FY27E revenue and 9.4x FY28E, the price only "works down" to a defensible ~7x sales by FY29 if consensus revenue ($3,328.2M FY27E, $4,014.9M FY28E, $4,726.8M FY29E — consensus, 15-16 analysts) is met or beaten. A single year at 12% growth instead of 19% costs roughly $250M of FY28 revenue and, at a constant 11x, about $19 per share. Falsifiable at each quarterly print.
• Gross margin holds at or above 64% through FY27. The entire re-rating from FY23 to today tracked the 45.5% → 64.8% margin expansion. Consensus does not publish a usable margin line here (we rejected it — see §1), so this is the market's implicit assumption, not a stated one. Falsifiable quarterly: Q1'26 held 64.8%. Any print below ~62% breaks the assumption and, at 11x sales, is worth an estimated 15-20% of the price.
• The company reaches GAAP profitability by FY28, and the market keeps paying a double-digit revenue multiple in the meantime. Consensus FY28E EPS is +$1.52 — but on a −$1.20 to +$4.57 range across fourteen analysts. This is the most fragile assumption in the price. Today's multiple is a sales multiple, which only survives if the loss is understood as a choice rather than a condition. If FY27 prints a wider loss than the −$0.30 consensus while revenue is merely in line, the market must either re-rate to a lower sales multiple or wait an extra two years for the earnings, and both outcomes are 25-35% price events.
• US reimbursement policy for residual-disease monitoring remains at least as favourable as today, through FY28. 98.2% of FY25 revenue is US. This assumption is not visible in any estimate line; it is embedded in all of them. Falsifiable by a single coverage determination.
• No further analyst upgrade is available. 24 Buy / 3 Hold / 0 Sell, consensus target $274.45 versus $270.36 spot. This is not an assumption so much as a measured fact about positioning: the sell-side's incremental buying pressure is spent. For the price to advance, estimates must rise, not ratings.

6b. The return bridge (why the multiple moves)

Expected return over a two-year horizon decomposes roughly as: revenue growth (+19-21% annually, consensus) + multiple compression (−) + shareholder yield (negative, −1 to −2% annually from stock-compensation dilution).

Our base case assumes multiple COMPRESSION, not expansion. We hold the base at 12x FY27E revenue against 13.5x FY26E today — that is a genuine de-rating on the same forward year, not the mechanical rolldown that a constant price produces. The reason is straightforward: consensus revenue growth decelerates from +35.9% (FY25 actual) to +21.3% (FY26E) to +19.0% (FY27E), and revenue multiples track growth rates closely in diagnostics. A business growing 19% does not sustainably command the multiple of one growing 36%.

So the base-case return of roughly +5% over the horizon is entirely revenue growth net of a modest de-rate and ongoing dilution. There is no multiple-expansion leg. That is the fragile part of the setup: the price already embeds the growth, so the only route to a large positive return is upward estimate revisions — which is precisely what the five-quarter beat pattern in §3 makes plausible, and precisely what a 24-of-27 Buy consensus makes hard to sustain.

The bull case is different in kind: it requires the multiple to hold at 15x forward rather than compress, which in practice means the beat cadence continues and consensus revenue for FY28 moves from $4,015M toward $4,500M+. That is an estimate-revision story, not a re-rating story.

6c. Variant perception (where we differ, what would surprise)

• We differ from consensus on the near-term revenue line, and by a lot. The street's Q2'26 estimate of $661.2M is below the Q1'26 actual of $696.6M — it models a sequential decline in a business with eight consecutive sequential increases and a five-quarter mean revenue beat of +13.1%. Our view: the probability of a Q2 revenue beat is materially higher than a coin flip, and the probability of a >10% beat is meaningful. Positive surprise, watchable 2026-08-06: revenue above ~$730M.
• We differ from the market on where the operating leverage is. The consensus path to FY28 profitability requires opex to grow at roughly half the rate of revenue for three years. FY25 and Q1'26 both did the opposite (loss widened year-over-year on much higher revenue). Our view: the crossover happens later than FY28, or happens because growth slows rather than because leverage arrives. Negative surprise, watchable quarterly: an FY26 operating loss wider than FY25's −$309.9M.
• We do NOT have a variant view on the franchise itself. On the quality of the asset — the 64.8% gross margin, the recurring surveillance model, the net-cash self-funding — we agree with the 24 Buy ratings. Where we depart is entirely on entry price, and per house rule a no-edge-on-the-asset name defaults toward Hold. That is exactly what has happened here.
• The under-discussed risk is geographic, not competitive. Five straight years at ~98% US revenue means one payer regime is the entire business. The market prices this as a growth stock; it is structurally a single-jurisdiction regulated-reimbursement stock. Negative surprise, watchable: any adverse national coverage determination on residual-disease monitoring — a step-function, not a gradual, risk.

Synthos fair values

• Bear ~$195 — 8x FY27E revenue ($3,328.2M) = EV $26.63B + $0.86B net cash = $27.49B ÷ 141.5M shares. Assumes growth decelerates toward the mid-teens, the beat cadence breaks, and the market applies a mature-diagnostics multiple to a still-unprofitable business. −28%.
• Base ~$285 — 12x FY27E revenue ($3,328.2M) = EV $39.94B + $0.86B = $40.80B ÷ 141.5M. Assumes 19% growth lands, gross margin holds ~65%, and the multiple de-rates modestly from 13.5x FY26E to 12x FY27E in line with decelerating growth. +5%.
• Bull ~$360 — 15x FY27E revenue ($3,328.2M) = EV $49.92B + $0.86B = $50.78B ÷ 141.5M. Assumes the beat cadence continues, FY27-28 consensus revenue is revised up 8-12%, and the market holds today's multiple rather than compressing it. Above the $330 street high. +33%.

Base sits ~5% above spot, bracketed by a −28% bear and a +33% bull. That is a roughly symmetric-to-slightly-favourable distribution with a very thin central expectation — the textbook definition of a Hold.

7. Technicals — no edge either way

• Price $270.36, −4.7% from the fifty-two-week high of $283.80 (the quote file separately shows $288.04 — a minor vendor discrepancy, noted).
• Above a rising 50-day average ($246.03) by 9.9% and above a rising 200-day average ($221.05) by 22.3%. Both trends intact and upward.
• RSI 48.2 — dead neutral. There is no oversold entry signal and no overbought warning. MACD +3.80, mildly positive.
• Relative strength is extreme: +102.3% over twelve months versus +19.9% (S&P) and +23.9% (Nasdaq-100); +30.4% over three months versus +5.1% and +3.8%. Natera has outperformed the index by 82 points in a year.
• Read: the chart is healthy and offers no tactical entry. A stock 4.7% off its high with a neutral RSI going into earnings is a coin flip on the print — which is precisely the argument for not initiating at spot.

8. Insider activity

Two Form 4 filings dated 2026-07-29 covering trades on 2026-07-27 and 2026-07-28:

• Jonathan Sheena (director, co-founder): sold 288 shares at $260.49 and 191 shares at $254.07, leaving 245,723 shares held.
• Matthew Rabinowitz (director, Executive Chairman): sold 1,718 shares at $260.49, leaving 2,276,125 shares held.

Read: programmatic, immaterial, not a signal. These are dribble-sized disposals — Rabinowitz sold 0.075% of his holding — consistent with pre-arranged trading plans. There is no evidence of a concentrated insider exit near the high in this file, which is a meaningful absence given the stock's 102% run. Equally, there is no insider buying to point to.

9. Knowledge base — one claim, and it is thin

The knowledge base contains one claim naming Natera:

All-In (2025-10-09, conviction 85, bullish, horizon: thesis) — categories genetic diagnostics / genomics / life sciences: "Genetic diagnostics is a huge winner — Natera grew from a $1M seed to ~$22B cap leading prenatal, oncology recurrence, and transplant testing; the genome project still pays dividends."

How to read it honestly. This is a favourable, high-conviction claim that names the ticker and correctly identifies the three franchises. But it is (a) a retrospective observation about a company that had already succeeded, not a forward call; (b) framed at a ~$22B market capitalisation, and the company is now $38.7B — the stock has advanced 76% against that reference point, so even taken at face value the claim's implied entry has long passed; and (c) a single voice, single date, with no follow-up and no test tag.

kb_claim_count: 1. kb_breadth: 1. There is no Synthos conviction lane on this ticker. This dive is fundamentals- and quant-driven, which is an accepted and precedented outcome — but it means the verdict carries no panel support and must stand entirely on the arithmetic above. We searched for "NTRA" and "Natera" across 51,928 knowledge-base entries; the single hit above is the complete result.

10. Moat and competitive position

Natera's moat is a validated, reimbursed, longitudinal assay plus the clinical-evidence base behind it — not a technology moat in the semiconductor sense. Sequencing chemistry is broadly available; what is not broadly available is the accumulated clinical validation, the payer contracts, the physician-ordering relationships and the operational scale to run millions of tests at 64.8% gross margin.

The evidence that this moat is real and widening: gross margin expanded 19.3 points in two years while volume roughly doubled. A commoditising business does the opposite. The evidence that the moat is bounded: it is a single-country moat (98.2% US), it is a regulator- and payer-granted moat rather than a technological one, and 27.1% of revenue must be reinvested in R&D each year to defend it.

Moat: real, narrow, and jurisdictionally contingent. Strong enough to justify a premium multiple; not strong enough to make the multiple safe.

11. Management and capital allocation

CEO Steven Leonard Chapman; Matthew Rabinowitz Executive Chairman and co-founder (holding 2.28M shares); Jonathan Sheena co-founder and director.

Capital allocation is straightforward and, on the evidence, disciplined: no dividend, no buyback (repurchases $0 in every year of the file), no meaningful M&A ($16.0M of net acquisitions in FY25, $0 in FY24 and FY23), no debt raised, no equity sold for cash. Every dollar of the $861.8M net-cash position was accumulated from operations, and every dollar of investment has gone into R&D ($624.1M) and commercial expansion (SG&A $1,177.3M). Capex is light at $106.2M (4.8% of revenue).

The one criticism: 14.9% of revenue is paid in stock ($354.4M). That is a real, ongoing transfer from shareholders, it exceeds the entire GAAP net loss, and it has driven a 15.1% increase in the share count over seven quarters. It is the price of retaining talent in a competitive field, but it should be treated as an expense when computing what you are actually paying — free cash flow of $109.1M against $354.4M of stock compensation means the business does not yet generate cash on an owner's-earnings basis.

12. Verdict, kill-criteria and flip conditions

Hold. Natera is a materially better business than its GAAP income statement suggests — 64.8% gross margin expanding, 35.9% FY25 revenue growth accelerating to 38.8% in Q1'26, $861.8M of net cash, positive free cash flow for two consecutive years, and a five-quarter revenue-beat cadence averaging +13.1% that the street still has not corrected for. It is also, at $270.36, a stock that has doubled in twelve months, trades 1.5% above its own consensus price target, carries 24 of 27 raters already at Buy, prices at 13.5x forward revenue with no full-year GAAP profit modelled until FY28 (on a −$1.20 to +$4.57 range), and reports earnings in two days.

We do not initiate here. Base fair value of $285 is 5% above spot; the bear case is 28% below. That distribution does not pay for the earnings-date risk.

The specific reason it is Hold and not Avoid: the Q2 revenue consensus of $661.2M is below the Q1 actual of $696.6M, which is an unusually clear analytical error given the sequential record, and the business behind the price is genuinely excellent.

Staged entry — for a position we do not yet own:

1. No purchase at spot ($270).

2. Tranche 1 (1-2% starter) below ~$235 — a normal post-earnings or momentum-unwind pullback to the rising 50-day average, roughly 10-13% cheaper, at ~10x FY27E revenue.

3. Tranche 2 (to ~3%) below ~$210 — a test of the rising 200-day average ($221) that holds, at ~9x FY27E revenue. That is the price at which the base case pays 35%+ rather than 5%.

Pre-registered KILL / do-not-buy criteria:

• The revenue beat cadence breaks — any quarter that misses or merely meets consensus revenue removes the single strongest quantitative support for the multiple.
• Gross margin prints below ~62% — the 45.5% → 64.8% expansion is the entire re-rating; reversal invalidates the premium.
• FY26 full-year operating loss comes in wider than FY25's −$309.9M — this would confirm that opex grows with revenue rather than below it, and pushes the profitability crossover beyond the horizon the price assumes.
• An adverse US coverage determination on residual-disease monitoring — a step-function risk to 98.2% of the revenue base.
• The rising 200-day average (~$221) is decisively lost on company-specific news — the primary trend, and our tranche-2 level, would both be broken.

Pre-registered FLIP TO BUY:

• A price of $220-235 with the operating thesis intact — same business, 15-20% cheaper, base case paying 25-30% instead of 5%. This is the single most likely path to a Buy and requires nothing to change except the quote.
• A Q2/Q3 revenue print above ~$730M with gross margin ≥65% AND an operating loss that narrows year-over-year — the combination that would prove the leverage is arriving on schedule and would drive genuine upward estimate revision rather than the mere beat-and-spend pattern of FY25.
• Any material international revenue inflection (EMEA/APAC combined above ~5% of revenue) — this would add a growth leg the market currently assigns zero value to, because it has been zero for five years.

Where NTRA fits in the Synthos Framework Portfolio. The diagnostics / genomics sleeve, as a quality growth holding — target 2-3% at the right price, 0% at this one. It is complementary rather than redundant to a sequencing-tools position (ILMN, covered separately in this batch): Illumina sells the instruments and consumables, Natera sells the reimbursed clinical test built on top of them — different customers, different revenue models, and one is a ~6% grower while the other is a ~20% grower. Logged as a tracked Synthos call (Hold, do not initiate) as of 2026-08-04 at $270.36, with a pre-registered Buy trigger at $235.

Single biggest risk: valuation, not the franchise. At 13.5x FY26E revenue with the stock up 102% in twelve months and priced above the consensus target, Natera must not merely execute — it must execute better than a street that already rates it 24-Buy expects. A perfectly good quarter is a de-rating event.

Most fragile assumption in the price: that GAAP profitability arrives around FY28. It is the assumption that justifies paying a sales multiple rather than demanding a cash-flow multiple; it rests on fourteen analysts whose FY28 EPS estimates span −$1.20 to +$4.57; and it requires operating expenses to grow at half the rate of revenue for three years after two consecutive periods in which they grew faster.

Provenance and disclosures

• Traceability: 1 tagged knowledge-base claim names Natera (All-In, 2025-10-09, conviction 85, bullish, skill 1.0). Breadth 1, net conviction positive but thin, and framed at a ~$22B market capitalisation against today's $38.7B. Searched across 51,928 entries for "NTRA" and "Natera"; no other hits. No Synthos conviction lane exists on this ticker — the dive is fundamentals- and quant-driven, an accepted and precedented outcome.
• Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates, prices, technicals and knowledge-base claims 2026-08-04. All market data drawn exclusively from scripts/deepdive/vti_data/NTRA_data.json. No figure in this dive was retrieved from any other source, from memory, or by inference beyond the arithmetic explicitly shown.
• Vendor data rejected (see §1): the entire forecast EBITDA and EBIT series in est — every year carries large negative EBITDA alongside positive, rising net income (FY30E: EBITDA −$2,097.9M versus net income +$720.2M), which is arithmetically impossible; the associated forecast SG&A line appears to have absorbed cost of goods sold. Only revenueAvg and epsAvg were used from that block.
• Data gaps stated, not papered over: seg_prod provides no oncology / women's health / organ health revenue split for FY24 or FY25 (only "Product" $2,295.8M and "Licensing and other" $10.3M), so no claim in this dive rests on a franchise-level split. FY29E and FY30E rest on 8 and 12 EPS contributors; the FY28E EPS range spans −$1.200 to +$4.572. The quote's implied share count (~143.2M) differs from the Q1'26 weighted diluted count (141.5M) by ~1.2%; per-share arithmetic uses 141.5M.
• Fair-value method: scenario multiples applied to consensus FY27E revenue ($3,328.2M, 15 analysts), plus net cash of $861.8M, divided by 141.5M shares. Bear 8x, base 12x, bull 15x. Stated arithmetic only — no discounted-cash-flow model was built, and none should be inferred.
• Timing caveat: written two days before the Q2'26 print (2026-08-06), deliberately, to frame the entry question around it. The result may move the picture materially; the recommendation is explicitly to hold rather than initiate ahead of it.
• Not investment advice. Independent research, educational and informational only, never personalised.
• Version: 2026-08-04-full.